Overview

Efficacy of Nicotine Acid on Dyslipidaemia in Patients With Metabolic Syndrome

Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
Placebo controlled evaluation of effectiveness of nicotine acid in treatment of postprandial dyslipidemia in patients with metabolic syndrome. Nicotine acid decreases postprandial hyperlipidaemia in patients with metabolic syndrome which reduces the low-grade inflammation and the risk of atherosclerosis.
Phase:
Phase 3
Details
Lead Sponsor:
GWT-TUD GmbH
Collaborators:
Technische Universität Dresden
University of Regensburg
Treatments:
Nicotine